BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 22514659)

  • 1. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
    Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
    Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
    Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
    Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
    Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
    PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
    Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
    Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
    Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
    FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
    J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
    Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
    Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.